Pulse BiosciencesPLSE
Recorded

Pulse Biosciences 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Rick WiseAnalyst

Alrighty. My name is Rick Wise, as I've mentioned before today. I'm truly thrilled, and it is my pleasure to welcome Pulse Biosciences. To my right here, Paul LaViolette, Pulse Bio's Chief Executive and Co-Chairman. Jon Skinner, Chief Financial Officer, is in the audience. Thank you both for being here. I've had the pleasure, I have to brag about something, of knowing Paul since 1989 when he was head of C. R. Bard's vascular division. Who would have thought in 1989, Paul, we'd be sitting here all these years later with your Exactly most exciting story to date.

Rick WiseAnalyst

Is that a good opening?

Paul LaVioletteCEO and Co-Chairman

That is a perfect opening, and I'll take it from there. Thank you, Rick. It's an honor to be on the stage with you. I do think the history, as we've walked through the growth of interventional medicine, is relevant. Maybe I left the clicker over here. I'll comment just briefly on Pulse Biosciences. We'll make some forward-looking statements today, so here's our disclaimer. Let me just talk about our mission and what drove me to the company after multiple decades, starting in med tech in 1980 and having been at this now for over 45 years, is a unique combination of characteristics.

Paul LaVioletteCEO and Co-Chairman

The novelty of the technology this company possesses, the ubiquitous nature of ablation, and how a novel energy can be an enabler to the conversion of so many procedures to a less invasive and more patient-friendly alternative with all the benefits of health economics, all the benefits of improved outcomes. There's so much here to unpack with Pulse Biosciences. It is, in fact, that which had me join the company two years ago as a CEO, and it's been a remarkable run in many ways because the company has become manifest in the last year with clinical data, clinical trials, product development advances on multiple fronts, and that's what we'll spend time talking about today. The mission of Pulse Biosciences is very clearly focused on the fulfillment of the potential of nsPFA.

Paul LaVioletteCEO and Co-Chairman

We've seen, and we'll talk more about pulsed field ablation and this new dynamic of pulsed electric field ablation. But nsPFA is a truly different form of energy, and Pulse Biosciences is uniquely positioned to be the first and the best, and maybe the only practitioner of this energy form. What is amazing to me is that we've seen energies come along over time and take over markets. We now, I think, have the potential to see nsPFA take over multiple markets, and that's what we find so intriguing as a business prospect. It is an energy that delivers a unique mechanism of action. It's an energy that we are rigorously developing with product development and clinical milestones, and one where in every direction we turn, we see significant potential advantage for patients. As I mentioned, I have a lot of experience in the medical device field.

Paul LaVioletteCEO and Co-Chairman

I'm joined by a great senior executive team, maybe the most notable of which are Darrin Uecker and Liane Teplitsky, Chief Technology and Operating Officers respectively. The three of us have a lot of experience developing and commercializing significant technologies, and we really feel well-prepared to seize on this opportunity. We were joined earlier this year in a full-time status by David Kenigsberg. He's a key opinion leader electrophysiologist. He became full-time Chief Medical Officer. We'll talk about the clinical trial he just helped to orchestrate, but we've now completely enrolled our pivotal IDE in atrial fibrillation, and no better evidence of his impact on the company than that success. Bob Duggan spearheads a board of directors that is extremely experienced. Bob has a very long track record in life sciences, drug development, med tech development.

Paul LaVioletteCEO and Co-Chairman

He's been at this for over 50 years, remarkably successful as an entrepreneur, as an investor, and we're privileged to have his support and involvement literally on a daily basis. Over the last year, we've substantially increased our financial capabilities. We strengthened our balance sheet, ending last quarter with $189 million in cash and marketable securities. Our goal is to exit the year closer to $200 million. We feel very strongly about that. We've been quite opportunistic as the stock price has grown. We've added capital in a very minimally dilutive way to support our core strategies, which are highlighted by our focus on atrial fibrillation, running those studies, generating that data, advancing our product pipeline, now beginning to invest incrementally in manufacturing startups so that we can get a head start on preparation for market launch at scale in 2028.

Paul LaVioletteCEO and Co-Chairman

We are going to continue to expand our IDE activity with new indications and an expansion into the persistent population, which we'll talk about, and do everything necessary to support this platform's readiness to take on and be disruptive in significant markets. Just a minute on the technology itself. Energy is used to ablate tissue, to eliminate unwanted tissues in the body, and to restore normal bodily function. Radiofrequency or thermal ablation is used millions of times a month, and it is destructive. It destroys the tissue you're targeting. It also increases the risk of destroying adjacent tissues and producing unwanted adverse effects. There's no question it's beneficial, but there's also no question about the desirability of changing away from that thermal modality. Then, of course, we observe first-generation microsecond PFA come along.

Paul LaVioletteCEO and Co-Chairman

Nothing more notable than the Boston Scientific FARAPULSE launch, which, of course, upended the atrial fibrillation market. You do need to think about this as a first-generation technology. It is microsecond PFA that is relatively early stage, relatively slow, relatively inefficient form of delivering a pulsed electric field. It operates ever so close to the thermal range, so if you deliver too much microsecond pulsing in a given space, you will create a thermal effect, and we have seen that in the marketplace, leading to product recalls and changes in labeling and technique. Nanosecond PFA, where we operate, is not 10 times faster, it is not 100 times faster, it is 1,000-fold faster in terms of pulse duration, and we add to that a meaningful, a multiple increase in the energy that we deliver in terms of voltage amplitude.

Paul LaVioletteCEO and Co-Chairman

As a result of that unique combination, we produce a different form of energy that produces a different mechanism of action in the tissue, and we are starting to see the clinical outcome of that. Those unique properties combine to create enormous invention potential. This is one of the slides we have had to update most frequently because our issued patents have grown by more than 10% this year with an incremental 30 issued patents. This is one of the most comprehensively protected technology platforms one will find. We have intellectual property on how to generate these nPulse waveforms. We have methods applications. For instance, the application of nsPFA to cardiac tissue is patented. We have intellectual property on the catheter design that is so broad that it is not even limited to the use of nsPFA.

Paul LaVioletteCEO and Co-Chairman

Our catheter has many advantages, and one cannot reproduce that catheter design or function regardless of whether you are using nsPFA or microsecond PFA or refrigeration, for all of that matter. Now, let us talk about the market that we are going after principally, and that is the atrial fibrillation market. I think everybody is aware that AFib is the most common atrial arrhythmia in man. You see from this blue chart here, there are nearly 2 million new diagnoses per year and estimated more than 10 million prevalence in the United States. Now, this is not a benign affliction.

Paul LaVioletteCEO and Co-Chairman

Patients with AFib have a sixfold increase in stroke risk, and it is not only a condition that causes quality of life impairment, but holds fundamental outcomes risks that no patient wants to live with, and the solutions for which have historically been some combination of anticoagulation and antiarrhythmic drugs, which also produce significant side effects. Patients are in a bind, and what is really driving this market is, number one, increased incidence in the population. We are aging less gracefully. Patients have higher body weight. They have hypertension that leads to stresses on the cardiac structure, which leads to atrial stretching, which causes atrial fibrillation. So we are actually living a life that causes this disease to happen more often.

Paul LaVioletteCEO and Co-Chairman

In addition to that, we're wearing iWatches, which allow us to diagnose it, and we can prescribe to a wearable ambulatory cardiac monitoring patch that will definitively diagnose AFib without even having to see a medical professional. This market is very large, it's growing very rapidly, and it's projected to more than double over the next five to seven years. That has led to a $4 billion ablation market, which is about half of the overall EP market, and again, that number will approach more like $10 billion in the early 2030s. This is a very significant market that has driven growth because of the movement of care for these patients closer and closer to ablation as a frontline indication.

Paul LaVioletteCEO and Co-Chairman

As we saw with the first PFA launch two years ago from Boston Scientific, if you can drop a catheter into that workflow, it will move through and wipe out the prior generation of energy, which PFA did with RF, and we fully expect nsPFA has the potential, and we will demonstrate the outcomes necessary to believe that this will do the same. Next-generation PFA will do the same to first-generation PFA as first-generation PFA did to RF. We feel very good about that prospect, and our job now is to really deliver on that promise with a development and clinical program that really is built upon, I would say, these four pillars. What does nsPFA deliver to cardiac tissue and in the hands of an electrophysiologist that fundamentally has disruptive potential for the AFib market? Number one, we simply make better lesions.

Paul LaVioletteCEO and Co-Chairman

This is a challenge of delivering energy into atrial tissue and delivering transmural ablations that isolate electrical signals, do it quickly, do it reliably, do it consistently, do it safely, and have that ultimately translate into improved outcomes. We're seeing that unquestionably, and we'll talk about the data in support of my comments. This is about speed. How do you take care of 2 million patients a year? You need throughput. You need outcomes that deliver a single-intervention effectiveness, and we're seeing that. While our pivotal outcomes data look fantastic from our feasibility study and will be validated with our IDE results, there's incontrovertible evidence of the workflow advantages this device has in the lab, in the hands of the electrophysiologist. Our ablation times are faster. The number of ablations we have to deliver are fewer.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day